SGLT-2 inhibition in IgA nephropathy: the new standard of care?
Jonathan Barratt, Jürgen Floege
Topics & Concepts
MedicineNephropathyKidney diseaseAdverse effectDapagliflozinDiseaseIntensive care medicineInternal medicineEndocrinologyDiabetes mellitusType 2 diabetesRenal Diseases and GlomerulopathiesDiabetes Treatment and ManagementPlatelet Disorders and Treatments